Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2016

View Archived Issues

Mixed results for KRP-203 in ulcerative colitis phase II trial

Linaclotide shows preclinical potential for bladder hyperactivity

Amgen's FOLR1-BiTE antibody constructs target folate receptor 1 in ovarian tumors

PF-04236921 effective in phase II trial for Crohn's disease

FDA approves Flucelvax Quadrivalent

Ironwood's IWP-953 for ocular hypertension

MorphoSys and MD Anderson form alliance to develop anticancer antibodies

Eli Lilly initiates phase I trial of LY-3298176 for type 2 diabetes

FDA approves Janssen Pharmaceutical's Invokamet line extension

Dart NeuroScience patents glycine transporter 1 inhibitors

Roche describes beta-secretase inhibitors

Dart NeuroScience discloses PDE2A inhibitors

Janssen Pharmaceutica reports RORgammaT receptor modulators

Merck & Co. patents orexin receptor antagonists

FDA clears IND application for Abeona's ABO-101

Theratechnologies presents preliminary primary endpoint results from phase III ibalizumab trial

New company Thunderbolt Pharma acquires rights to Astellas' BAFF/APRIL antagonist program

Hillhurst Biopharmaceuticals receives grant for HBI-002 in sickle cell disease

Big DNA becomes Iceni Pharmaceuticals with focus on repurposing cancer therapies

Monsanto labels Bayer's acquisition proposal "incomplete and financially inadequate"

InDex Pharmaceuticals receives grant for preclinical development of DIMS compounds

PDL BioPharma commits to equity investment in Noden Pharma

FDA approves Roche CMV test for use in hematopoietic stem cell transplant recipients

GM-604 shows safety and efficacy in patients with ALS worldwide

Asterias Biotherapeutics reports long-term results of phase I study of AST-OPC1

Novartis expands access to Ensemble Therapeutics' IL-17 antagonist program

AstraZeneca launches Tagrisso in Japan

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026